Brano Therapeutics

AnaCardio

This biopharmaceutical company develops oral small-molecule drugs to improve cardiac contractility in patients with heart failure.

Braveheart Bio

This biopharmaceutical company develops small-molecule therapeutics to treat patients with hypertrophic cardiomyopathy and other serious cardiovascular conditions.

Cardior

This company develops RNA-based therapeutics designed to prevent, repair and reverse heart diseases for patients with cardiac dysfunctions.

NanoPhoria

This company develops an inhalable nano-drug delivery platform and therapeutics for patients with heart failure and other cardiovascular diseases.

Cardurion Pharmaceuticals

This clinical-stage biotechnology company develops therapeutic drugs for patients with heart failure and other cardiovascular diseases.

Revier Therapeutics

This company develops orally available small molecules targeting class IIa histone deacetylases to treat patients with heart failure and atherosclerotic cardiovascular diseases.

Phlox Therapeutics

This company develops RNA-based gene therapies to treat patients with rare genetic heart diseases, including cardiomyopathies and laminopathies.

Marea Therapeutics

This biotechnology company develops medicines for cardiometabolic and cardioendocrine diseases using human genetic data for patients with unmet medical needs.